Leading the Way in Life Science Technologies

GEN Exclusives

More »
GEN Podcasts Back to Item »

ROUNDTABLE DISCUSSION ON BIOTECH/PHARMA DEALS

- Martina Molsbergen, VP, Business Development, Crucell; Barbara Yanni, Chief Licensing Officer, Merck & Co.; David Colpman, Senior VP, Business Development, Shire Pharmaceuticals; and Joern-Peter Halle, Head, Early-Stage Licensing, Merck Serono, a division of Merck KGaA



  • Click here to Login or to Register for free.

    You will be taken back to your selected item after Login/Registration.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »